Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 15, 2005. The report details corporate actions regarding share repurchases and updates on directors' interests in company shares.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Share Repurchase (June 14): 1,100,000 shares purchased at 1,349.9 pence per share.
- Share Repurchase (June 15): 890,000 shares purchased at 1,336.92 pence per share.
- Total Treasury Shares (Post-June 15): 98,283,000 shares.
- Shares in Issue (Excluding Treasury): 5,846,666,356 shares.
Material Changes
The primary material change is the reduction of outstanding shares through two consecutive buyback transactions executed on June 14 and June 15, 2005, utilizing authority granted at the Annual General Meeting on May 25, 2005. Additionally, the GSK Trust transferred 3,592 shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the June 14 and June 15 share repurchases against the company's cash position.
- Confirm the updated total share count (5,846,666,356) for earnings per share calculations.
- Note that three directors (Dr J-P Garnier, Dr T Yamada, Mr J S Heslop) hold indirect interests via the GSK Trust.
- Confirm that the repurchased shares are held in Treasury and not retired.